Castle Biosciences Wins 2026 Genomics Innovation Award
FRIENDSWOOD, Texas, May 12, 2026 Castle Biosciences announced that its AdvanceAD-Tx™ gene expression profiling test received the prestigious 2026...
JAK inhibitor
Advertisement
Alkermes Reports Strong Phase 3 LUMRYZ Trial Data
DUBLIN, Ireland, May 12, 2026 Alkermes announced positive topline results from the pivotal REVITALYZ Phase 3 clinical trial evaluating...
Incyte Opzelura Shows Durable Atopic Dermatitis Benefit
WILMINGTON, Del., May 7, 2026 Incyte announced positive 24-week long-term results from the Phase 3 TRuE-AD4 clinical trial evaluating...
Karyopharm SENTRY Trial Advances Myelofibrosis Treatment
Newton, Massachusetts, USA, April 21, 2026 In a major development in hematologic oncology, Karyopharm Therapeutics Inc. has announced that...
LEO Pharma Gains FDA sNDA Acceptance for ANZUPGO
Madison, New Jersey, U.S. | April 15, 2026 LEO Pharma has announced that the U.S. Food and Drug Administration...
Advertisements
Merck Animal Health’s NUMELVI™ Wins FDA Approval
Rahway, New Jersey, USA — February 25, 2026 The U.S. Food and Drug Administration (FDA) has approved NUMELVI™ (atinvicitinib...
AbbVie Raises 2025 Outlook as Skyrizi and Rinvoq Surge
NORTH CHICAGO, Ill., November 2, 2025 — AbbVie Inc. (NYSE: ABBV), a global biopharmaceutical leader, has raised its annual...
FDA Updates RINVOQ® Label for Inflammatory Bowel Disease Use
NORTH CHICAGO, Illinois, October 13, 2025 – AbbVie Inc. (NYSE: ABBV) announced that the U.S. Food and Drug Administration...
Health Canada Approves Bylvay for Cholestatic Pruritus in ALGS
OTTAWA, Canada, September 9, 2025 — Health Canada has granted approval to Bylvay™ (odevixibat) for the treatment of cholestatic...
Advertisement
